Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Standard BioTools Inc.

Standard BioTools Inc. (LAB) Stock Overview

Explore Standard BioTools Inc.’s financial performance, market position, analyst ratings, and future outlook.

LAB●NASDAQ
HealthcareMedical - Equipment & Services
$0.80
$0.00(0.01%)
U.S. Market opens in 49h 55m

Standard BioTools Inc. (LAB)

Meyka AI Score

Z

Key Financials

Market Cap313.2M
P/E Ratio-3.48
EPS (TTM)$-0.07
ROE-0.18%
Fundamental Analysis

AI Price Forecasts

1 Month$0.63
3 Months$1.07
1 Year Target$0.49

LAB Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Standard BioTools Inc. (NASDAQ: LAB) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Standard BioTools Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of LAB on the NASDAQ shows an RSI of 44.35, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $0.49 for the NASDAQ listing.

Key metrics behind Standard BioTools Inc.'s NASDAQ-traded stock include a P/E ratio of -3.48 and a market capitalization of 313.2M. Combined with our AI analysis, these give both institutional and retail investors a clear view of LAB on the NASDAQ.

Price Performance (NASDAQ: LAB)

1-Day Change
-0.01%
5-Day Change
-9.56%
1-Month Change
-11.00%
3-Month Change
-20.00%
6-Month Change
-36.51%
Year-to-Date (YTD) Change
-37.50%
1-Year Change
-37.98%
3-Year Change
-66.67%
5-Year Change
-88.25%
All-Time (Max) Change
-94.29%

Contact Information

https://www.standardbio.com
650 266 6000
50 Milk Street, Boston, MA, 02109

Company Facts

3,890 Employees
IPO DateFeb 10, 2011
CountryUS
Actively Trading

Frequently Asked Questions